AstraZeneca announced Monday that the European Union drug regulator had accepted its market authorization application for accelerated assessment for sipavibart, an investigational
AstraZeneca announced on Tuesday its decision to initiate the global withdrawal of its COVID-19 vaccine, citing a surplus of available updated vaccines